Skip to main content

Δ-11-Tetrahydrocannabinol Facts

Cannabinoid; Cannabinoid; Cannabinoid CB1 receptor partial agonist

Description

Δ-11-THC (Δ-9,11-tetrahydrocannabinol) is a trace cannabinoid of the classical cannabinoid class. It is a positional isomer of Δ9-THC, distinguished by an exocyclic double bond that sharply reduces potency.[1] This structural change weakly activates cannabinoid receptors in the brain, producing dramatically diminished effects compared to standard THC.

Subjective effects include mild relaxation, possible mood shift, and slight cognitive blunting — though no controlled human study has confirmed the compound is psychoactive. The experience, if it occurs at all, is weaker than even Δ8-THC — closer to the floor of the cannabinoid range than a recognizable high.

No dependence data exist; animal studies suggest lower acute toxicity than Δ9-THC,[2] but no safe dose has been established for humans. The dominant risk is the unregulated market — products are untested for purity, and "3× stronger than Δ9-THC" marketing claims almost certainly reflect confusion with a different, genuinely potent compound.

Dose and duration

No dose or duration recorded for any route.

Body and dependence

Acute toxicity
Low
Chronic toxicity
Not assessed
Physical dependence
Negligible
Psychological dependence
Low
Withdrawal
None recorded
Compulsive redosing
Negligible

Tolerance

Builds
Slow
Fully resets after
3 weeks
Carries over to
Δ9-THC; Δ8-THC; other CB1 agonists

Effectslikely at a common dose

Perception
none likely · 20 possible, including Spatial disorientation, Vestibular distortion, Visual acuity suppression
Body
Body high; Body scan awareness; Dry mouth; +22 possible, including Heart rate perception changes, Motor control impairment, Dizziness
Thinking
none likely · 35 possible, including Cognitive impairment, Memory suppression, Decision impairment
Feeling
Euphoria; +8 possible, including Anxiety, Paranoia, Emotional lability
Self
none likely · 10 possible, including Derealization, Communication suppression, Craving
Time
Time alteration; +3 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Pregnancy and lactation
Relative
Cardiovascular disease; Psychotic disorders; Concurrent sympathomimetic or epinephrine use

Combinations60 recorded

Dangerous (11)
Ketamine, DXM, PCP; Opioids; GHB, Baclofen; GHB, GBL; Ibogaine; Local anesthetics; MAOIs; NDRIs (Wellbutrin); Salvia, Ibogaine; SNRIs; Synthetic cannabinoids
Caution (34)
See full page: psychedex.org/substances/delta-11-thc
Not graded (15)
Not listed never means safe.

Seek help immediately if

Natural cannabis rarely causes a medical emergency — "greening out" is: pale/sweaty skin, dizziness, nausea or vomiting, anxiety or panic, rapid heartbeat, feeling faint — and usually passes with rest.

Seek emergency help for these — far more likely with synthetic cannabinoids ("spice" / K2):

  • Seizures
  • Severe chest pain; very fast or irregular heartbeat
  • Unresponsiveness or extreme drowsiness
  • Severe agitation, aggression, or psychosis
  • Repeated vomiting; difficulty breathing

What to do

  1. Sit or lie them down somewhere calm, cool, and quiet
  2. Reassure them — cannabis panic and "greening out" pass with time
  3. Offer sips of water; a little sugar can help if they feel faint
  4. Recovery position if nauseated, drowsy, or vomiting
  5. Stay with them and monitor
  6. For seizures, chest pain, unresponsiveness, or severe agitation, call emergency services

Natural cannabis "greening out" resolves with rest, calm, and time, with no lasting harm. Synthetic cannabinoids are unpredictable and can cause seizures, cardiac events, kidney injury, and severe agitation that needs emergency care.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Kriwacki RW, Makriyannis A (1989) The conformational analysis of delta 9- and delta 9,11-tetrahydrocannabinols in solution using high resolution nuclear magnetic resonance spectroscopy. — Molecular pharmacology PMID:2539557
  2. [2]
    ^Beardsley PM, Scimeca JA, Martin BR (1987) Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. — The Journal of pharmacology and experimental therapeutics PMID:3033218
Print version
Report an issue